欧美一区二区在线观看-欧美一区二区在线视频-欧美一区二区综合亚洲国产-欧美一区午夜福利在线-欧美一区亚洲-欧美一区在

SMO Services & Solutions

?     About SMO ClinPlus

ClinPlus provides site management services to both local and global companies in research development in pharmaceuticals, medical devices, and health-related products. Since its establishment in 2009, ClinPlus has been committed to undertaking clinically valued innovative drugs projects. It has participated in over 3400 SMO projects and established 24 business units and a significant competitive advantage in multiple segmented diseases such as hematological tumors, thoracic tumors, gastrointestinal tumors, urological tumor, endocrinology department, infectious medicine department, dermatology and immunology department and rheumatism immunity branch. It has also brought into the market over 170 drugs domestically and worldwide. Provide high quality site management service for well-known pharmaceutical companies including MSD, PXL, Akesobio, Zelgen, Novartis, Hengrui, Bristol-Myers Squibb, Henlius, Eli Lilly, and Labcorp.

?     Site/Resource Coverage

As of Sep 30, 2024, ClinPlus has more than 4,692 professionals serving over 940 clinical trial research institutions, out of the 1,300 ones it is able to cover. ClinPlus is able to fulfill the needs of our clients in most projects by being able to provide services in about 190 cities in most provinces across the country.

  • Unblinded BU
  • Urinary Tumors BU
  • Digestive Oncology BU
  • Phase I BU
  • SSU BU
  • Blood Tumors BU
  • CART BU
  • Gastroenterology BU
  • Gynecology BU
  • Immunodermatolog BU
  • Pediatrics BU
  • Cardiovascular BU
  • Endocrine BU
  • Lung Cancer BU
  • Hepatopathy BU
  • Respiratory BU
  • Breast Cancer BU
  • Antibiotics BU
  • ICU BU
  • Neurology & Neurosurgery BU
  • Psychiatry BU
  • Medical Device & Surgical BU
  • Ophthalmology & Otorhinolaryngology BU
?     Core Market
  • From the therapeutic perspective

    We cover the mainstream disease spectrum, such as tumor, endocrine, cardiovascular, respiratory, virus, etc.

  • From the perspective of clinical trial stages

    We are involved in Phase I-III and post-marketing surveillance

  • From the client's perspective

    Clients include world-renowned new drug R&D companies, CRO companies, and most domestic new drug companies and mainstream pharmaceutical companies.

?     Achievements
  • 2015 :

    ClinPlus was awarded the first PD-1 project in China: Bristol-Myers Squibb's research in Navulamumab for treating lung cancer;

  • 2016 :

    ClinPlus was awarded the first CAR-T project: JW's Therapeutics's research in CD19 compound antigen receptor T cell injection for treating B-cell non-Hodgkin lymphoma;

  • 2018 :

    The first monoclonal antibody drug in China for treating hyperlipidemia-Rebbegan by Amgen Biotech, awarded to ClinPlus, was successfully listed in the market;

  • 2019 :

    The first direct oral anti-hepatitis C virus drug, Sofosbuvir tablets, awarded to ClinPlus, was approved to be sold in the market.

    The world's first approved biologic Beliuximab for treating systemic lupus erythematosus, awarded to ClinPlus, was approved to be sold in the market.

    The first domestic human papillomavirus vaccine in China-Xinkonin, awarded to ClinPlus, was approved to be sold in the market.

  • 2022 :

    ClinPlus assisted sponsor to get NDA for the world's first and only approved ADC drug targeting Trop-2, the first domestic double antibody and the world's first PD-1/CTLA-4 double antibody and other innovative drugs.

  • 2023 :

    ClinPlus assisted the launch of multiple innovative drugs in China. CAR-T product for treating leukemia, used for the treatment of graft-versus-host disease. The only immunotumor therapy approved in China for neoadjuvant therapy of NSCLC. Oral direct anti-hepatitis C virus drugs. PD-L1 inhibitor for the treatment of small cell lung cancer.First Clinical Trial Program for CAR-T Therapy. Domestic Human Papillomavirus (HPV) Vaccine.

?     Four modules of model establishment
Purpose:

To form a model by fully integrating previous performances in operation, including site selection, SSU, patient enrollment, risk management, quality control, database, investigators' fee, patient expenses. By establishing a relatively realistic and reliable model during the start of the project, we can help our clients find a more robust and practical implementation plan to improve efficiency and maximize the benefits of resource allocation.

?      Corporate Social Responsibility

As of June 30, 2024, ClinPlus has served more than 310,000 subjects and participated in more projects for chronic and rare diseases, such as the Thalassemia Gene Therapy Project, Acromegaly Project, Gosheimer's Disease Project, Hemophilia Project, and Spinal Muscular Atrophy Project, which provided opportunities to help patients enjoy the most cutting-edge therapeutic medicines and means in the world.

In 2023, the Company organized its employees to carry out blood donation totaling 6,800 ml, with a total of 34 people participating in blood donation.

主站蜘蛛池模板: 男女久久久视频2019 | 久青草国产视频 | 久久综合给合久久狠狠狠97色69 | KUAIMAO CC| 久久久高清免费视频 | 免费光看午夜请高视频 | 一本久道久久综合久久鬼色 | 扣扣影视在线 | 国产精品亚洲AV色欲一区二区三区 | 日日碰狠狠躁久久躁AV | 无码日本精品久久久久久 | 久久99爱视频 | 亚洲精品天堂在线观看 | 成人国产精品一级毛片视频 | 最近最新中文字幕在线手机版 | 免费看欧美日韩一区二区三区 | 国产精品久久国产精品99 gif | 欧美aa级片 | 99re免费在线视频 | 91精品国产欧美一区二区 | 狼人社区 | 国产欧美日韩一区二区赛车 | 免费麻豆文化传媒 | 99re在线观看视频 | 麻豆成人AV久久无码精品 | 日本按摩xxxxx高清 | 永久AV狼友网站在线观看 | 日本高清视频免费观看 | www.黄色毛片 | 桃花综合久久久久久久久久网 | 国产精品久久久久久久久久98 | 国产自产对白一区 | 韩国伦理片在线2018 | 日本精品人妻无码久久久 | 欧美精品18videosex性俄罗斯 | 51视频精品全部免费最新 | 亚洲国产中文字幕 | 免费高清岛国在线观看 | 中文字幕一区在线播放 | 亚洲精品无码一区二区卧室 | 人妻无码AV中文系列免费 |